Market expansion proponents
Underneath the clearly demarcated party lines of the debate, there were some out-of-character comments. Minority Leader Rep. Gephardt, for example, became a cheerleader for wider drug use during his attack on the bill. Explaining why the drug program should be a benefit and not insurance, Gephardt declared, "when we come to prescription drug benefits, everybody makes a claim, because everybody needs prescription drugs." California Democrat Rep. Stark got caught up in the description of a more generous Democratic benefit. "We are begging to spend this surplus and not waste it on a relief from the inheritance tax...With that money alone, we could provide an added benefit at a low enough premium and eliminate the copay so that we could include all the Medicare beneficiaries in a generous, dependable benefit with a reliable premium that would be the same across the country and allow the seniors to get their drugs from any provider in the country"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth